DESTINY-Breast03 Phase 3 Study Results
Best Percentage Change in Tumor Size by ICR in BC Cohorts
Best Percentage Change in Sum
of Diameters From Baseline
20
0
-20
-40
40
00
100
80
ggg
-80
-100
HER2-positive
Cohort 1 HER2-positive BC (n = 32)
Parts 1/2: T-DXd 5.4 mg/kg and Nivolumab 360 mg
Best (minimum) Percentage Change
n
31
Mean
-53.0
SD
33.82
Median
-57.0
CR
PR
Non-CR/PR
Treated with T-DXd
5.4 mg/kg in part 1
Min
-100
Max
13
Best Percentage Change in Sum
of Diameters From Baseline
100-
880
60
40
20
20
0
-20
-40
-60
-80-
-100-
HER2-low
PR
Non-CR/PR
• Hormone receptor
negative
Cohort 2 HER2-low BC (n = 16)
Part 2: T-DXd 5.4 mg/kg and Nivolumab 360 mg
Best (minimum) Percentage Change
SD
28.56
n
Mean
15
-29.2
Median
-35.0
Min
-68
Max
54
BC, breast cancer; CR, complete response; HER2, human epidermal growth factor receptor 2; ICR, independent central review; PR, partial response; RDE, recommended dose for expansion; SD, standard deviation;
T-DXd, trastuzumab deruxtecan.
2 of 3 patients with HER2-positive BC treated at T-DXd 5.4 mg/kg RDE in combination with nivolumab 360 mg in part 1 are shown. In cohort 2, 1 of 3 patients who were hormone receptor negative had a confirmed PR. The
line at 20% indicates progressive disease, and the line at -30% indicates a PR.
ESMO BC 2022 #1620 Oral
65
Daiichi-SankyoView entire presentation